NASH
November 27, 2020
InSphero CEO Jan Lichtenberg extends holiday greetings from our teams in Switzerland and the United States, and looks back on the highlights of 2020: a tumultuous year shaped by a […]
May 1, 2020
An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
March 13, 2020
As the coronavirus epidemic prompts cancellations of scientific meetings around the world and shifts to virtual settings, we have been working on alternative methods to keep you informed of advances […]
December 18, 2019
InSphero CEO Jan Lichtenberg muses about how far 3D cell-based technology has come since InSphero was founded in 2009 and shares the latest news about how our disruptive 3D technology […]
September 23, 2019
Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019
InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog. She […]
July 17, 2019
InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
August 20, 2018
Pharma companies racing to accelerate the drug discovery for chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here's how […]
June 18, 2018
In honor of the inaugural International NASH Day, Insphero explains why we need better preclinical models for non-alcoholic steatohepatitis (NASH) disease drug discovery. Non-alcoholic fatty liver disease (NAFLD) is one of […]